STUDY DESIGN: Prospective case series. OBJECTIVES: Male infertility is a common sequela of spinal cord injury (SCI). Fatherhood is a goal in this group of young patients; however, most are anejaculatory. Penile vibratory stimulation is recommended as the first line of treatment for this condition. Our study evaluated the safety and efficacy of a new device designed to induce ejaculation in these patients. SETTING: The Miami Project to Cure Paralysis, Miami, FL, USA. METHODS: The Viberect-X3 (Reflexonic, Frederick, MD, USA) was applied to 30 consecutive anejaculatory men with SCI whose level of injury was T10 and rostral. RESULTS: The ejaculatory success was 77% (23/30). No adverse events occurred, and there were no malfunctions of the device. CONCLUSION: In this first report on the efficacy of the Viberect-X3 for treatment of anejaculation in men with SCI, we conclude that the device is safe and effective for inducing ejaculation in men with SCI. Recommendation of the Viberect-X3 versus other devices intended for this purpose should not be made until randomized controlled trials are performed.
STUDY DESIGN: Prospective case series. OBJECTIVES:Male infertility is a common sequela of spinal cord injury (SCI). Fatherhood is a goal in this group of young patients; however, most are anejaculatory. Penile vibratory stimulation is recommended as the first line of treatment for this condition. Our study evaluated the safety and efficacy of a new device designed to induce ejaculation in these patients. SETTING: The Miami Project to Cure Paralysis, Miami, FL, USA. METHODS: The Viberect-X3 (Reflexonic, Frederick, MD, USA) was applied to 30 consecutive anejaculatory men with SCI whose level of injury was T10 and rostral. RESULTS: The ejaculatory success was 77% (23/30). No adverse events occurred, and there were no malfunctions of the device. CONCLUSION: In this first report on the efficacy of the Viberect-X3 for treatment of anejaculation in men with SCI, we conclude that the device is safe and effective for inducing ejaculation in men with SCI. Recommendation of the Viberect-X3 versus other devices intended for this purpose should not be made until randomized controlled trials are performed.
Authors: Paolo Capogrosso; Christian Fuglesang S Jensen; Giulia Rastrelli; Josep Torremade; Giorgio I Russo; Amr Abdel Raheem; Anders Frey; Mikkel Fode; Mario Maggi; Yacov Reisman; Carlo Bettocchi; Giovanni Corona Journal: Sex Med Date: 2021-06-02 Impact factor: 2.491